Access Pharmaceuticals Implements 1 for 5 Reverse Stock Split

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ask Centralassd	LSE:AKCA	London	Ordinary Share	GB0034031905	ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Ask Centralassd

LSE:AKCA

London

Ordinary Share

GB0034031905

ORD 5P(ASSD CITY CENTRE REST SHS & CASH)

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

Access Pharmaceuticals Implements 1 for 5 Reverse Stock Split

05/06/2006 2:30pm

PR Newswire (US)

Ask Centralassd (LSE:AKCA)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Ask Centralassd Charts.

DALLAS, June 5 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (ACCP.OB) (formerly AKCA.OB) today announced a one for five reverse stock split. The reverse split will take effect and the shares will begin trading on a post-split basis at the opening of business on Monday, June 5, 2006. The Company's new ticker symbol is "ACCP" and the Company's common stock will be traded on the OTC Bulletin Board. The shareholders at a meeting May 19, 2006 approved a five to one reverse stock split of the Company's common stock. After giving effect to the one for five reverse stock split, the Company will have approximately 3.5 million shares outstanding. Shareholders will be notified by American Stock Transfer & Trust Company, Access' stock transfer agent, regarding the process for receiving new share certificates. The reverse split brings the number of shares outstanding and the share price to a level more consistent with companies of our size and stage of development. Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include AP5346, currently in Phase II clinical testing of patients with ovarian cancer and head and neck cancer, and our mucoadhesive liquid technology for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com/. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission. DATASOURCE: Access Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President & CFO, Access Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations, Donald C. Weinberger, Wolfe Axelrod Weinberger LLC, +1-212-370-4500 Web site: http://www.accesspharma.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AKCA Ask Centralassd